Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2025 Mar 1;185(3):266-272.
doi: 10.1001/jamainternmed.2024.7178.

Doxycycline Postexposure Prophylaxis and Sexually Transmitted Infection Trends

Madeline Sankaran  1 , David V Glidden  2 , Robert P Kohn  1 , Trang Q Nguyen  1 , Oliver Bacon  1   2 , Susan P Buchbinder  1   2 , Monica Gandhi  2 , Diane V Havlir  2 , Courtney Liebi  2 , Anne F Luetkemeyer  2 , Janet Q Nguyen  2 , Jorge Roman  3 , Hyman Scott  1   2   3 , Thiago S Torres  4 , Stephanie E Cohen  1   2
Affiliations
Comment

Doxycycline Postexposure Prophylaxis and Sexually Transmitted Infection Trends

Madeline Sankaran et al. JAMA Intern Med. .

Abstract

Importance: Increasing rates of sexually transmitted infections (STIs) have been associated with rises in serious morbidity. While doxycycline postexposure prophylaxis (doxyPEP), a strategy in which individuals take doxycycline, 200 mg, after condomless sex to prevent bacterial STIs, has been shown to be efficacious in randomized clinical trials, doxyPEP's potential effect on population-level STI incidence is unknown.

Objective: To assess the association of citywide doxyPEP guideline release with reported chlamydia, gonorrhea, and early syphilis cases in men who have sex with men (MSM) and in transgender women in San Francisco, California.

Design, setting, and participants: This population-level interrupted time series analysis of reported San Francisco STI cases measured monthly cases of chlamydia, gonorrhea, and early syphilis prior to (July 2021-October 2022) and after (November 2022-November 2023) release of citywide doxyPEP guidelines in October 2022. All reported chlamydia, gonorrhea, and early syphilis cases among MSM and transgender women in San Francisco during the period of analysis were included. Data were analyzed November 2023 to July 2024.

Exposure: Release of doxyPEP citywide guidelines.

Main outcomes and measures: The primary outcome was the percentage change between projected and observed chlamydia, gonorrhea, and early syphilis cases in the 13-month postexposure period.

Results: Citywide, there were 6694 cases of chlamydia, 9603 cases of gonorrhea, and 2121 cases of early syphilis among MSM and transgender women during the analytic period. STI cases among MSM and transgender women decreased significantly compared with model projections for chlamydia (-6.58% per month; 95% CI, -7.99% to -5.16%) and early syphilis (-2.68% per month; 95% CI, -3.75% to -1.60%) after doxyPEP implementation. By the end of the 13-month postperiod in November 2023, chlamydia and early syphilis cases decreased -49.64% (95% CI, -59.05% to -38.06%) and -51.39% (95% CI, -58.21% to -43.46%), respectively, compared with projected cases. There was a significant increase in monthly gonorrhea cases compared with projections (1.77% per month; 95% CI, 0.87% to 2.67%).

Conclusions and relevance: This study suggests that San Francisco's doxyPEP guideline release was associated with decreases in reported cases of chlamydia and early syphilis, but not gonorrhea, among MSM and transgender women in San Francisco. Further analyses are needed to assess whether declines are sustained and monitor for adverse consequences, including antimicrobial resistance. Supporting doxyPEP implementation for MSM and transgender women at risk for STIs could have a significant impact on the nationwide STI epidemic.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Buchbinder reported grants from Merck and GlaxoSmithKline as well as nonfinancial support from Gilead Sciences and ViiV Healthcare outside the submitted work. Dr Havlir reported grants from National Institutes of Health and nonfinancial support from ViiV Healthcare outside the submitted work. Dr Luetkemeyer reported nonfinancial support from Mayne Pharmaceutical, Cepheid Lab, and Hologic Lab during the conduct of the study as well as grants from GlaxoSmithKline, Gilead, Cepheid, and Merck outside the submitted work. Dr Cohen reported nonfinancial support from Mayne Pharmaceutical, Cepheid Lab, and Hologic Lab during the conduct of the study as well as grants from the Global Antibiotic Research & Development Partnership/Innovivo and Roche outside the submitted work. No other disclosures were reported.

Comment on

References

    1. US Centers for Disease Control and Prevention . Sexually transmitted infections surveillance 2022: national overview. Accessed May 30, 2024. https://stacks.cdc.gov/view/cdc/147167
    1. Oliver SE, Aubin M, Atwell L, et al. . Ocular syphilis—eight jurisdictions, United States, 2014-2015. MMWR Morb Mortal Wkly Rep. 2016;65(43):1185-1188. doi:10.15585/mmwr.mm6543a2 - DOI - PubMed
    1. California Department of Public Health . California STI surveillance: 2021. data graph set. Accessed May 30, 2024. https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/STD-...
    1. Grey JA, Bernstein KT, Sullivan PS, et al. . Estimating the population sizes of men who have sex with men in US states and counties using data from the American Community Survey. JMIR Public Health Surveill. 2016;2(1):e14. doi:10.2196/publichealth.5365 - DOI - PMC - PubMed
    1. Pollock ED, Clay PA, Keen A, et al. . Potential for recurrent mpox outbreaks among gay, bisexual, and other men who have sex with men—United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(21):568-573. doi:10.15585/mmwr.mm7221a1 - DOI - PMC - PubMed

MeSH terms